BioWorld

May 11, 2009

View Archived Issues

Exelixis, BI Enter Autoimmune Agreement Worth up to $354M

Exelixis Inc. and German drugmaker Boehringer Ingelheim GmbH entered a deal potentially worth $354 million to discover, develop and commercialize autoimmune disease therapies. (BioWorld Today) Read More

Biotech Clusters Face Challenges, but Jobs and Capital Still Exist

Read More

H1N1 Swine, H5N1 Bird Flu Both Still Long Way from Pandemic

Read More

Dendreon Offering Raises $230M for Provenge Launch Preparation

Read More

CDC: H1N1 Bullet Not Dodged Just Yet, Threat not Over

Read More

Other News To Note

Read More

Clinic Roundup

Read More